132 related articles for article (PubMed ID: 8376814)
1. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children.
Belshe RB; Anderson EL; Walsh EE
J Infect Dis; 1993 Oct; 168(4):1024-9. PubMed ID: 8376814
[TBL] [Abstract][Full Text] [Related]
2. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.
Murphy BR; Prince GA; Walsh EE; Kim HW; Parrott RH; Hemming VG; Rodriguez WJ; Chanock RM
J Clin Microbiol; 1986 Aug; 24(2):197-202. PubMed ID: 3755730
[TBL] [Abstract][Full Text] [Related]
3. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old.
Tristram DA; Welliver RC; Mohar CK; Hogerman DA; Hildreth SW; Paradiso P
J Infect Dis; 1993 Jan; 167(1):191-5. PubMed ID: 8418166
[TBL] [Abstract][Full Text] [Related]
5. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
Murphy BR; Sotnikov A; Paradiso PR; Hildreth SW; Jenson AB; Baggs RB; Lawrence L; Zubak JJ; Chanock RM; Beeler JA
Vaccine; 1989 Dec; 7(6):533-40. PubMed ID: 2692334
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection.
Piedra PA; Glezen WP; Kasel JA; Welliver RC; Jewel AM; Rayford Y; Hogerman DA; Hildreth SW; Paradiso PR
Vaccine; 1995 Aug; 13(12):1095-101. PubMed ID: 7491817
[TBL] [Abstract][Full Text] [Related]
7. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.
Murphy BR; Sotnikov AV; Lawrence LA; Banks SM; Prince GA
Vaccine; 1990 Oct; 8(5):497-502. PubMed ID: 2251875
[TBL] [Abstract][Full Text] [Related]
8. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.
Piedra PA; Grace S; Jewell A; Spinelli S; Bunting D; Hogerman DA; Malinoski F; Hiatt PW
Pediatr Infect Dis J; 1996 Jan; 15(1):23-31. PubMed ID: 8684872
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults.
Gonzalez IM; Karron RA; Eichelberger M; Walsh EE; Delagarza VW; Bennett R; Chanock RM; Murphy BR; Clements-Mann ML; Falsey AR
Vaccine; 2000 Mar; 18(17):1763-72. PubMed ID: 10699324
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of subgroup-specific peptides of the G protein of respiratory syncytial virus for characterization of the immune response.
Akerlind-Stopner B; Utter G; Norrby E; Mufson MA
J Med Virol; 1995 Oct; 47(2):120-5. PubMed ID: 8830114
[TBL] [Abstract][Full Text] [Related]
11. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis.
Piedra PA; Grace S; Jewell A; Spinelli S; Hogerman DA; Malinoski F; Hiatt PW
Pediatr Infect Dis J; 1998 Mar; 17(3):217-24. PubMed ID: 9535249
[TBL] [Abstract][Full Text] [Related]
12. Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement.
Tristram DA; Welliver RC; Hogerman DA; Hildreth SW; Paradiso P
Vaccine; 1994 May; 12(6):551-6. PubMed ID: 8036830
[TBL] [Abstract][Full Text] [Related]
13. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.
Murphy BR; Walsh EE
J Clin Microbiol; 1988 Aug; 26(8):1595-7. PubMed ID: 2459154
[TBL] [Abstract][Full Text] [Related]
14. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine.
Kakuk TJ; Soike K; Brideau RJ; Zaya RM; Cole SL; Zhang JY; Roberts ED; Wells PA; Wathen MW
J Infect Dis; 1993 Mar; 167(3):553-61. PubMed ID: 8440926
[TBL] [Abstract][Full Text] [Related]
15. Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV).
Murphy BR; Prince GA; Collins PL; Hildreth SW; Paradiso PR
Vaccine; 1991 Mar; 9(3):185-9. PubMed ID: 2042390
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with a heterologous respiratory syncytial virus chimeric FG glycoprotein demonstrates significant subgroup cross-reactivity.
Oien NL; Brideau RJ; Thomsen DR; Homa FL; Wathen MW
Vaccine; 1993; 11(10):1040-8. PubMed ID: 8212825
[TBL] [Abstract][Full Text] [Related]
17. Influence of live respiratory syncytial virus priming on the immune response generated by a recombinant vaccine candidate, BBG2Na.
Goestch L; Plotnicky-Gilquin H; Champion T; Beck A; Haeuw JF; Nguyen T; Bonnefoy JY; Corvaïa N
Vaccine; 2000 Jun; 18(24):2648-55. PubMed ID: 10781850
[TBL] [Abstract][Full Text] [Related]
18. The envelope proteins from purified respiratory syncytial virus protect mice from intranasal virus challenge.
Levine S; Dillman TR; Montgomery PC
Proc Soc Exp Biol Med; 1989 Apr; 190(4):349-56. PubMed ID: 2928348
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee.
Hsu KH; Lubeck MD; Davis AR; Bhat RA; Selling BH; Bhat BM; Mizutani S; Murphy BR; Collins PL; Chanock RM
J Infect Dis; 1992 Oct; 166(4):769-75. PubMed ID: 1527411
[TBL] [Abstract][Full Text] [Related]
20. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
